Journal
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
Volume 32, Issue 3, Pages 443-446Publisher
SAGE PUBLICATIONS INC
DOI: 10.1038/jcbfm.2011.184
Keywords
brain imaging; depression; dopamine; Parkinson's disease; positron emission tomography; 5-HT
Categories
Funding
- Eli-Lilly
- Lundbeck
- GlaxoSmithKline
- BristolMyersSquibb
- SK Life Sciences
- US NIH NIDA [DA025096]
- Canadian Institutes of Health Research (CIHR)
- National Alliance for Research on Schizophrenia and Depression (NARSAD)
- Canada Foundation for Innovation (CFI)
- Alexander von Humboldt Foundation (AvH)
- Ontario Mental Health Foundation (OMHF)
- Ontario Ministry of Research and Innovation
Ask authors/readers for more resources
Monoamine oxidase A (MAO-A) is an important target in the pathophysiology and therapeutics of major depressive disorder, aggression, and neurodegenerative conditions. We measured the effect of changes in MAO-A substrate on MAO-A binding in regions implicated in affective and neurodegenerative disease with [C-11]-harmine positron emission tomography in healthy volunteers. Monoamine oxidase A V-T, an index of MAO-A density, was decreased (mean: 14%+/- 9%) following tryptophan depletion in prefrontal cortex (P < 0.031), and elevated (mean: 17%+/- 11%) in striatum following carbidopa-levodopa administration (P < 0.007). These findings suggest an adaptive role for MAO-A in maintaining monoamine neurotransmitter homeostasis by rapidly compensating fluctuating monoamine levels. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 443-446; doi: 10.1038/jcbfm.2011.184; published online 21 December 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available